Home » BTG Pays 160 Million Pounds for Rival Biocompatibles
BTG Pays 160 Million Pounds for Rival Biocompatibles
BTG, the pharmaceutical group perhaps best known for its varisolve varicose veins treatment, is paying around £160 million to buy drug device group Biocompatibles, adding oncology products to its portfolio.
Guardian
Guardian
Upcoming Events
-
07May
-
14May
-
30May